BA: University of Guelph, S.Sc. Hon, Molecular Biology and Genetics Guelph, Ontario, Canada 1992.
PhD: University of Toronto, PhD Department of Laboratory Medicine Toronto, Ontario, Canada 1999.
Fellowship: Childrens Hospital Los Angeles Department of Pediatrics Division of Research Immunology/BMT Los Angeles, CA, 1999-2002.
Regulating human pluripotent stem cell; somatic cell reprogramming in iPSC; human embryonic stem cell physiology and differentiation; hESC; cystic fibrosis
Experimental Hematology and Cancer Biology, Cancer and Blood Diseases
Integrated Genomic Analysis of Diverse Induced Pluripotent Stem Cells from the Progenitor Cell Biology Consortium. Stem Cell Reports. 2016; 7:110-125.
Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cells. The Journal of Clinical Investigation. 2015; 125:3103-3116.
G-CSF resistance of ELANE-mutant neutropenia depends on SERF1-containing truncated-neutrophil elastase aggregates. The Journal of Clinical Investigation. 2025; 135:e177342.
Loss of ATG5 in Humans Causes Syndromic Congenital Dyserythropoietic Anemia with Impaired Mitophagy in Late Stages of Terminal Erythropoiesis. Blood. 2024; 144:1084.
The Dominant Negative Acting VPS4AE228Q Mutation Causes Dyserythropoiesis in Human iPSC-Derived Erythroblast Cultures That Phenocopies Cimdag Syndrome-Associated Anemia. Blood. 2024; 144:2458.
Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant. American Journal of Transplantation. 2024; 24:1634-1643.
A toxicology study of Csf2ra complementation and pulmonary macrophage transplantation therapy of hereditary PAP in mice. Molecular Therapy-Methods & Clinical Development. 2024; 32:101213.
CMV SEROSTATUS IS MOST IMPORTANT TO SELECT DONORS OF MONONUCLEAR CELL PRODUCTS AIMED TO THE GENERATION OF ANTI-CMV VIRUS-SPECIFIC T CELL (VSTS) PRODUCTS. Cytotherapy (Informa). 2024; 26:e20-e21.
Erythrocyte Disorders Mimicking Congenital Dyserythropoietic Anemia Based on Bone Marrow Pathology Exposed By Genetic Evaluation. Blood. 2023; 142:2459.
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults. Transplantation and Cellular Therapy. 2023; 29:305-310.
Carolyn M. Lutzko, PhD4/2/2020